(Q38422177)

English

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial

scientific article published on 15 October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial (English)

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

phase I clinical trial

0 references

monoclonal antibody

1 reference

based on heuristic

inferred from title

Serena Di Cosimo

1

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

author name string

Sriram Sathyanarayanan

2

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Johanna C Bendell

3

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Andrés Cervantes

4

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Mark N Stein

5

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Irene Braña

6

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Desamparados Roda

7

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Brian B Haines

8

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Theresa Zhang

9

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Christopher G Winter

10

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Sharda Jha

11

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Youyuan Xu

12

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Jason Frazier

13

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Richard A Klinghoffer

14

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Ann Leighton-Swayze

15

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Yang Song

16

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Scot Ebbinghaus

17

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

José Baselga

18

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

language of work or name

0 references

publication date

15 October 2014

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Clinical Cancer Research

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

21

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

49-59

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

1

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Targeting the mTOR signaling network for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Defining the role of mTOR in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

The phosphoinositide 3-kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

23 June 2018

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

31 August 2018

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

31 August 2018

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5705197

31 August 2018

Shortening the timeline of pediatric phase I trials: the rolling six design

1 reference

https://pubmed.ncbi.nlm.nih.gov/25320355

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-14-0940

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

release_tbgy3v6ugnaorcfxm73rbnllqy

1 reference

https://api.fatcat.wiki/v0/release/tbgy3v6ugnaorcfxm73rbnllqy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

1 reference

Europe PubMed Central

9 January 2018

http://europepmc.org/abstract/PMC/5705197

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38422177&oldid=1843972548"